180 Life Sciences’ stock price plunged 54% after it reverse split its shares to avoid delisting


The drug developer has been struggling since it suffered a regulatory setback in June. Now things have gotten worse.

Previous Developer Laconia wants to add density to entitled downtown Berkeley site
Next Peanut allergy drug developer Aimmune to cut 75 jobs as parent Nestlé looks at selling signature drug